Somatic genetic alterations of TCF12 (i.e. overexpression in hepatocellular carcinoma, ovarian and colorectal cancer, or compromise activity in anaplastic oligodendroglioma, prostate cancer) enhance cell proliferation, migration, and invasion, are related to more aggressive cancer course (9–13). This evidence concerns the gene TCF12 and prostate carcinoma.